Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00785044 · ClinicalTrials.gov registry record
Study Dosed With (123I-mIBG) for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event
A clinical trial, sponsored by GE Healthcare.
- Completed
- Registry status
- 471
- Enrollment target
NCT00785044 is a clinical trial that has completed, run by GE Healthcare. The registered enrollment target is 471 participants.
The verdict
NCT00785044 has completed, sponsored by GE Healthcare.
- COMPLETED
- Registry status
- 471 participants
- Enrollment target
Study Summary
The study was designed to study the utility of meta-iodobenzylguanidine (123I-mIBG) imaging to identify those participants with heart failure who would experience an adverse cardiac event during 24 months of follow-up from the administration date of 123I-mIBG in previous studies MBG311 or MBG312.
Interventions
- DRUG I-123 mIBG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 471 participants |
| Start Date | 2008-05 |
| Est. Completion | 2010-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00785044
The ClinicalTrials.gov registry entry for NCT00785044 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 471 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GE Healthcare, which has 99 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which I-123 mIBG is the first listed.
NCT00785044 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00785044 about?
NCT00785044 is a clinical study titled "Study Dosed With (123I-mIBG) for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event". The study was designed to study the utility of meta-iodobenzylguanidine (123I-mIBG) imaging to identify those participants with heart failure who would experience an adverse cardiac event during 24 months of follow-up from the administration date of 123I-mIBG in previous studies MBG311 or MBG312.
What is the current status of trial NCT00785044?
This trial is currently completed. The enrollment target is 471 participants. The study started on 2008-05. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00785044?
The interventions under investigation include: I-123 mIBG (DRUG).
Who is sponsoring clinical trial NCT00785044?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.